CAPTRUST Financial Advisors
SYRS

CAPTRUST Financial Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed – – 5180
2022
Q1 		$0 Buy
+8
New +$143 ﹤0.01% 5178

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors's SYRS Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 8 shares.

CAPTRUST Financial Advisors first reported a position in SYRS in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 8 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022.
  • CAPTRUST Financial Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q1 2022.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.